Mercaptopurina Silver (Mercaptopurine Monohydrate)

Mercaptopurine is metabolized inside cells to thio‑guanine nucleotides, which block the synthesis of purine bases needed for DNA and RNA. The drug also incorporates these fraudulent nucleotides into genetic material, disrupting replication and leading to cell death in rapidly dividing lymphocytes and cancer cells.

The dosage of Mercaptopurina Silver is individualized by the prescribing clinician based on the patient’s age, weight, disease severity, and laboratory parameters. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Safety data for mercaptopurine in pregnancy and lactation are limited. The drug may pose risks to the fetus and infant, and its use should be considered only when the potential benefits outweigh the possible harms. Pregnant or nursing patients must discuss options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both mercaptopurine and azathioprine are thiopurine immunosuppressants that share similar mechanisms, but azathioprine is a pro‑drug that is converted to mercaptopurine in the body. Mercaptopurine offers more predictable pharmacokinetics, while azathioprine may be preferred in some protocols for its dosing flexibility.

Mercaptopurina Silver should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, heat and direct sunlight to maintain stability and potency.

The medication is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. Patients should follow the exact dosing schedule and avoid crushing or splitting tablets unless instructed.

The most critical risks include severe bone marrow suppression, which can lead to anemia, infections or bleeding; hepatotoxicity; pancreatitis; and the rare possibility of secondary malignancies. Regular laboratory monitoring is essential to detect these complications early.

Individuals with known hypersensitivity to mercaptopurine or any component of the formulation, patients with severe liver disease, or those with a documented TPMT deficiency that predisposes them to extreme toxicity should avoid using Mercaptopurina Silver. Clinical judgment is required for all other contraindications.